SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma

SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling of macromolecules. Hydroxychloroquine (HCQ) is an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fei, Naomi, Wen, Sijin, Ramanathan, Rajesh, Hogg, Melissa E., Zureikat, Amer H., Lotze, Michael T., Bahary, Nathan, Singhi, Aatur D., Zeh, Herbert J., Boone, Brian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504806/
https://www.ncbi.nlm.nih.gov/pubmed/34002944
http://dx.doi.org/10.1111/cts.13029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504806/
https://www.ncbi.nlm.nih.gov/pubmed/34002944
http://dx.doi.org/10.1111/cts.13029

Ejemplares similares